Lipipor™ NLF Filter for Paediatric Parenteral Nutrition (EU) product photo Primary L

Lipipor™ NLF Filter for Paediatric Parenteral Nutrition (EU)

Features

  • 1.2 μm polyethersulfone membrane
  • Filtration of nutrient lipid containing solutions
  • Retention of particles, microorganisms and oversized lipid droplets
  • Air elimination 
  • For paediatric and neonatal care

Benefits

The Pall® Lipipor NLF offers patient protection against:

  • Particles: protecting the circulatory system against the undesirable systemic effects of particulate contamination in intravenous therapy and parenteral nutrition
  • Air: preventing air embolism
  • Enlarged lipid droplets: significantly reducing the number of enlarged droplets in emulsions and having at the same time an i mproved tolerance to enlarged droplet challenges
  • Micro-organisms: reducing the risk of infection due to inadvertently contaminated infusates, particularly with fungi of clinical importance

Filter for Parenteral Nutrition

  • The use of 1.2 μm filters in nutrient lipid emulsions has been advocated by professional organizations1.
  • Particulate contamination arises from infusion systems, components, manipulations2 and as precipitates due to interactions between nutrient components3 or drugs. Particles have been shown to cause damage to endothelial cells, trigger inflammation reactions and thrombus formation4. Particulate contamination leads to loss of functional capillary density, especially in tissue with a pre-existing ischemic insult and may lead to loss of organ function and organ failure 5, 6. Gross precipitation in admixtures has proven fatal and may not be visible when lipid is present3.
  • Air can become entrained in infusions due to degassing, disconnection or run-dry. It may not be visible in lipid-containing preparations. Air bubbles have been shown to cause tissue ischemia and to induce inflammation7.
  • Enlarged lipid droplets may arise in admixtures due to emulsion instability and due to the use of plastic bag containers8. The U.S. Pharmacopoeia suggests that the proportion of lipid present as droplets > 5 μm should not exceed 0.05% of the total fat present9. The infusion of unstable All-In-One (AIO) admixtures has been shown to cause tissue injury and oxidative stress to reticuloendothelial system organs10.
  • Microbiological contamination can occur in infusion systems inadvertently due to manipulations. Parenteral nutrition is an acknowledged risk for fungaemia, with Candida species being the most common organisms involved11. Malassezia furfur is emerging as an increasingly important pathogen in neonates. These fungi are able to survive and grow in lipid-containing preparations12.

References

  1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). Journal of Pediatric Gastroenterology and Nutrition (2005) 41:S1–S85
  2. Foroni LA. et al. J Parent Sci Technol (1993) 47: 311 - 4
  3. U.S. FDA Safety Alert. Am J Hosp Pharm (1994) 51:1427-8
  4. Oberdörster, G. et al. Particle and Fibre Toxicology (2005) 2: 8 - 43
  5. Lehr H.-A. et al. Am J Respir Crit Care Med (2002) 165: 514–520
  6. Walpot H et al. Anaesthetist (1989) 38:544-8.
  7. Muth CM, Shank ES New England Journal of Medicine (2000) 342: 476 - 482
  8. Driscoll DF and Bistrian BR Clinical Nutrition (2005) 24: 699-700
  9. USP, Chapter 729 Pharm Forum (2005) 31: 1448 –53
  10. Driscoll DF et al. Clinical Nutrition (2006) 25(5): 842-50
  11. Vazquez J et al. J Infect Dis (1993)168:195-201
  12. Robinson R and Ball P. NZ Hosp Pharm Assoc Oct 1996


* Required
Need Help?
Description

Features

  • 1.2 μm polyethersulfone membrane
  • Filtration of nutrient lipid containing solutions
  • Retention of particles, microorganisms and oversized lipid droplets
  • Air elimination 
  • For paediatric and neonatal care

Benefits

The Pall® Lipipor NLF offers patient protection against:

  • Particles: protecting the circulatory system against the undesirable systemic effects of particulate contamination in intravenous therapy and parenteral nutrition
  • Air: preventing air embolism
  • Enlarged lipid droplets: significantly reducing the number of enlarged droplets in emulsions and having at the same time an i mproved tolerance to enlarged droplet challenges
  • Micro-organisms: reducing the risk of infection due to inadvertently contaminated infusates, particularly with fungi of clinical importance

Filter for Parenteral Nutrition

  • The use of 1.2 μm filters in nutrient lipid emulsions has been advocated by professional organizations1.
  • Particulate contamination arises from infusion systems, components, manipulations2 and as precipitates due to interactions between nutrient components3 or drugs. Particles have been shown to cause damage to endothelial cells, trigger inflammation reactions and thrombus formation4. Particulate contamination leads to loss of functional capillary density, especially in tissue with a pre-existing ischemic insult and may lead to loss of organ function and organ failure 5, 6. Gross precipitation in admixtures has proven fatal and may not be visible when lipid is present3.
  • Air can become entrained in infusions due to degassing, disconnection or run-dry. It may not be visible in lipid-containing preparations. Air bubbles have been shown to cause tissue ischemia and to induce inflammation7.
  • Enlarged lipid droplets may arise in admixtures due to emulsion instability and due to the use of plastic bag containers8. The U.S. Pharmacopoeia suggests that the proportion of lipid present as droplets > 5 μm should not exceed 0.05% of the total fat present9. The infusion of unstable All-In-One (AIO) admixtures has been shown to cause tissue injury and oxidative stress to reticuloendothelial system organs10.
  • Microbiological contamination can occur in infusion systems inadvertently due to manipulations. Parenteral nutrition is an acknowledged risk for fungaemia, with Candida species being the most common organisms involved11. Malassezia furfur is emerging as an increasingly important pathogen in neonates. These fungi are able to survive and grow in lipid-containing preparations12.

References

  1. Guidelines on Paediatric Parenteral Nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), Supported by the European Society of Paediatric Research (ESPR). Journal of Pediatric Gastroenterology and Nutrition (2005) 41:S1–S85
  2. Foroni LA. et al. J Parent Sci Technol (1993) 47: 311 - 4
  3. U.S. FDA Safety Alert. Am J Hosp Pharm (1994) 51:1427-8
  4. Oberdörster, G. et al. Particle and Fibre Toxicology (2005) 2: 8 - 43
  5. Lehr H.-A. et al. Am J Respir Crit Care Med (2002) 165: 514–520
  6. Walpot H et al. Anaesthetist (1989) 38:544-8.
  7. Muth CM, Shank ES New England Journal of Medicine (2000) 342: 476 - 482
  8. Driscoll DF and Bistrian BR Clinical Nutrition (2005) 24: 699-700
  9. USP, Chapter 729 Pharm Forum (2005) 31: 1448 –53
  10. Driscoll DF et al. Clinical Nutrition (2006) 25(5): 842-50
  11. Vazquez J et al. J Infect Dis (1993)168:195-201
  12. Robinson R and Ball P. NZ Hosp Pharm Assoc Oct 1996
Specifications
Filter Medium 1.2 μm polyethersulfone Supor® membrane
Tubing Extension Non-phthalate microbore
Hold-up Volume
(filter housing and extension tubing)
0.8 mL
Flow Rate Maximum recommended pumped 75 mL/hr for lipid admixtures
Max Working Pressure 2 bar (30 psi)
Connectors ISO male luer outlet and ISO female luer inlet
 Usage  Single patient use 24 hours maximum
Type
In-line Filters
Use
Filtration
Ordering Information
Description Reorder Number Packaging

With microbore extension tubing, slide clamp, luer inlet and outlet

NLF2E 50 units per case
With luer inlet and outlet with collar case  NLF2NTE  50 units per case
Application
Hospital Infusion, Hospital Infusion